Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation

Journal of Inflammation

Volumn 8, Issue , 2011, Pages

  Murumalla, Ravi ^a   Bencharif, Karima ^a   Gence, Lydie ^a   Bhattacharya, Amritendu ^a   Tallet, Frank ^b   Gonthier, Marie Paule ^a   Petrosino, Stefania ^c   Di Marzo, Vincenzo ^c   Cesari, Maya ^a   Hoareau, Laurence ^a   Roche, Régis ^a  

^a UNIVERSITÉ DE LA RÉUNION   (France)

^b Centre Hospitalier Departemental Felix Guyon   (France)

^c CNR   (Italy)

Author keywords

human adipocyte; inflammation; SR141716A; TNF a

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADIPONECTIN; ANANDAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; CHOLESTEROL; CYTOKINE; INTERLEUKIN 6; ISOTOPE; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RIMONABANT; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DILUTION; DOWN REGULATION; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PROADIPOCYTE; PROTEIN EXPRESSION; STROMA CELL;

EID: 81055150430     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-8-33     Document Type: Article

References (49)

1. Metabolic complications of obesity. Grundy SM, Endocrine 2000 13 155 165 10.1385/ENDO:13:2:155 11186217
2. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H, J Clin Invest 2003 112 1821 1830 14679177 (Pubitemid 38063705)
3. Inflammatory mechanisms in the regulation of insulin resistance. Tilg H, Moschen AR, Mol Med 2008 14 222 231 18235842 (Pubitemid 351481853)
4. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA, J Clin Endocrinol Metab 2001 86 1930 1935 10.1210/jc.86.5.1930 11344187 (Pubitemid 32472900)
5. Impact of obesity in primary hyperlipidemias. Carmena R, Ascaso JF, Real JT, Nutr Metab Cardiovasc Dis 2001 11 354 359 11887432 (Pubitemid 33687824)
6. Endocannabinoids. Mechoulam R, Fride E, Di Marzo V, Eur J Pharmacol 1998 359 1 18 10.1016/S0014-2999(98)00649-9 9831287 (Pubitemid 28515716)
7. The endocannabinoid signalling system: biochemical aspects. Bisogno T, Ligresti A, Di Marzo V, Pharmacol Biochem Behav 2005 81 224 238 10.1016/j.pbb.2005.01.027 15935454 (Pubitemid 40812404)
8. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Andre A, Gonthier MP, Int J Biochem Cell Biol 42 1788 1801
9. Cannabinoids as novel anti-inflammatory drugs. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M, Future Med Chem 2009 1 1333 1349 10.4155/fmc.09.93 20191092
10. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, et al. Jama 2008 299 1547 1560 10.1001/jama.299.13.1547 18387931 (Pubitemid 351482794)
11. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, Jama 2006 295 761 775 10.1001/jama.295.7.761 16478899 (Pubitemid 43244304)
12. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A, Diabetes Care 2008 31 2169 2176 10.2337/dc08-0386 18678611
13. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, Lancet 2006 368 1660 1672 10.1016/S0140-6736(06)69571-8 17098084 (Pubitemid 46048528)
14. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, Lancet 2005 365 1389 1397 10.1016/S0140-6736(05)66374-X 15836887 (Pubitemid 40523733)
15. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Despres JP, Ross R, Boka G, Almeras N, Lemieux I, Arterioscler Thromb Vasc Biol 2009 29 416 423 10.1161/ATVBAHA.108.176362 19112166
16. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, Hennuyer N, Gilde A, Staels B, Schaeffer P, Bono F, Arterioscler Thromb Vasc Biol 2009 29 12 18 10.1161/ATVBAHA.108.168757 18845788
17. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, et al. Hepatology 2007 46 122 129 10.1002/hep.21641 17526015 (Pubitemid 47171928)
18. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, Nakayama M, Kaikita K, Obata T, Takeya M, Ogawa H, Circulation 2009 119 28 36 10.1161/CIRCULATIONAHA.108.811992 19103987
19. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Schafer A, Pfrang J, Neumuller J, Fiedler S, Ertl G, Bauersachs J, Br J Pharmacol 2008 154 1047 1054 10.1038/bjp.2008.158 18469848 (Pubitemid 351915060)
20. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Trayhurn P, Wood IS, Br J Nutr 2004 92 347 355 10.1079/BJN20041213 15469638 (Pubitemid 40277057)
21. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, et al. J Clin Endocrinol Metab 2006 91 3171 3180 10.1210/jc.2005-2679 16684820 (Pubitemid 44271774)
22. Identification of endocannabinoids and related compounds in human fat cells. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, Rouch C, Robert-Da Silva C, Chesne S, Lefebvre d'Hellencourt C, et al. Obesity (Silver Spring) 2007 15 837 845 10.1038/oby.2007.581 (Pubitemid 46740958)
23. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, Haffaf Y, Cesari M, Festy F, Histochem Cell Biol 2006 126 177 187 10.1007/s00418-005-0127-4 16395612
24. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M, Mol Pharmacol 2006 69 471 478 16282221 (Pubitemid 43121944)
25. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P, Mol Pharmacol 2003 63 908 914 10.1124/mol.63.4.908 12644592 (Pubitemid 36368998)
26. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, Tepel M, Zhu ZM, Biochem Biophys Res Commun 2007 354 427 433 10.1016/j.bbrc.2006.12.213 17223076 (Pubitemid 46172454)
27. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Motaghedi R, McGraw TE, Obesity (Silver Spring) 2008 16 1727 1734 10.1038/oby.2008.309
28. Leptin-regulated endocannabinoids are involved in maintaining food intake. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G, Nature 2001 410 822 825 10.1038/35071088 11298451 (Pubitemid 32303781)
29. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, Petrosino S, Tallet F, d'Hellencourt CL, Cesari M, et al. Obesity (Silver Spring) 2009 17 431 438 10.1038/oby.2008.591
30. [Inflammation, adipokines and obesity]. Clement K, Vignes S, Rev Med Interne 2009 30 824 832 10.1016/j.revmed.2009.03.363 19394723
31. Regulation of ABCA1 expression and cholesterol efflux during adipose differentiation of 3T3-L1 cells. Le Lay S, Robichon C, Le Liepvre X, Dagher G, Ferre P, Dugail I, J Lipid Res 2003 44 1499 1507 10.1194/jlr.M200466-JLR200 12754274 (Pubitemid 37279594)
32. Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. Verghese PB, Arrese EL, Soulages JL, Mol Cell Biochem 2007 302 241 248 10.1007/s11010-007-9447-0 17390217 (Pubitemid 47202340)
33. Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Zhao SP, Yang J, Li J, Dong SZ, Wu ZH, Int J Cardiol 2008 124 172 178 10.1016/j.ijcard.2006. 12.032 17395297 (Pubitemid 351173356)
34. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Tsubakio-Yamamoto K, Matsuura F, Koseki M, Oku H, Sandoval JC, Inagaki M, Nakatani K, Nakaoka H, Kawase R, Yuasa-Kawase M, et al. Biochem Biophys Res Commun 2008 375 390 394 10.1016/j.bbrc.2008.08.009 18703020
35. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, Hoareau L, Monteleone P, Roche R, Izzo AA, Di Marzo V, Br J Pharmacol 2007 152 676 690 17704823 (Pubitemid 350041540)
36. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther V, Mach F, Steffens S, Di Marzo V, Atherosclerosis 2009 205 433 441 10.1016/j.atherosclerosis.2008.12.040 19187936
37. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL, Life Sci 1998 63 L113 117 10.1016/S0024-3205(98)00322-1 9718088
38. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P, Am J Physiol Regul Integr Comp Physiol 2003 284 345 353 12399252
39. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G, J Clin Invest 2005 115 1298 1305 15864349 (Pubitemid 40629049)
40. CB(1) receptor antagonism: biological basis for metabolic effects. Di Marzo V, Drug Discov Today 2008 13 1026 1041 10.1016/j.drudis.2008.09.001 18824122
41. Targeting MCP-1 to reduce vascular complications of obesity. Ohman MK, Eitzman DT, Recent Pat Cardiovasc Drug Discov 2009 4 164 176 19925437
42. TNF-alpha alters visfatin and adiponectin levels in human fat. Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P, Horm Metab Res 2007 39 250 255 10.1055/s-2007-973075 17447161 (Pubitemid 46715881)
43. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG, J Clin Pharmacol 2007 47 642 652 10.1177/0091270007299358 17392496 (Pubitemid 46632153)
44. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W, Endocrinology 2008 149 2557 2566 10.1210/en.2007-1515 18276749 (Pubitemid 351574492)
45. Regulation of adiponectin release and demonstration of adiponectin mRNA as well as release by the non-fat cells of human omental adipose tissue. Fain JN, Buehrer B, Tichansky DS, Madan AK, Int J Obes (Lond) 2008 32 429 435 10.1038/sj.ijo.0803745 (Pubitemid 351414815)
46. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, et al. J Biol Chem 2009 284 1803 1812 19008231
47. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Migrenne S, Lacombe A, Lefevre AL, Pruniaux MP, Guillot E, Galzin AM, Magnan C, Am J Physiol Regul Integr Comp Physiol 2009 296 929 935 10.1152/ajpregu.90824. 2008 19211723
48. Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. Bellocchio L, Cervino C, Vicennati V, Pasquali R, Pagotto U, J Neuroendocrinol 2008 20 Suppl 1 130 138 18426512 (Pubitemid 351559286)
49. CB1 antagonists for obesity - what lessons have we learned from rimonabant? Di Marzo V, Despres JP, Nat Rev Endocrinol 2009 5 633 638 10.1038/nrendo.2009.197 19844251